- Home
- WLYB vs SPRY Comparison
WLYB vs SPRY Comparison
Compare WLYB & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- SPRY
- Stock Information
- Founded
- WLYB 1807
- SPRY 2015
- Country
- WLYB United States
- SPRY United States
- Employees
- WLYB N/A
- SPRY N/A
- Industry
- WLYB Books
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- SPRY Health Care
- Exchange
- WLYB Nasdaq
- SPRY Nasdaq
- Market Cap
- WLYB 2.1B
- SPRY 1.8B
- IPO Year
- WLYB N/A
- SPRY N/A
- Fundamental
- Price
- WLYB $42.11
- SPRY $9.57
- Analyst Decision
- WLYB
- SPRY Strong Buy
- Analyst Count
- WLYB 0
- SPRY 5
- Target Price
- WLYB N/A
- SPRY $31.00
- AVG Volume (30 Days)
- WLYB 238.0
- SPRY 3.1M
- Earning Date
- WLYB 09-04-2025
- SPRY 11-12-2025
- Dividend Yield
- WLYB 3.34%
- SPRY N/A
- EPS Growth
- WLYB N/A
- SPRY N/A
- EPS
- WLYB 1.78
- SPRY N/A
- Revenue
- WLYB $1,670,600,000.00
- SPRY $112,339,000.00
- Revenue This Year
- WLYB $1.45
- SPRY N/A
- Revenue Next Year
- WLYB $2.70
- SPRY $188.92
- P/E Ratio
- WLYB $23.00
- SPRY N/A
- Revenue Growth
- WLYB N/A
- SPRY 22367.80
- 52 Week Low
- WLYB $37.27
- SPRY $9.38
- 52 Week High
- WLYB $52.90
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- WLYB 67.63
- SPRY 25.20
- Support Level
- WLYB $39.63
- SPRY $9.38
- Resistance Level
- WLYB $42.54
- SPRY $10.15
- Average True Range (ATR)
- WLYB 0.01
- SPRY 0.65
- MACD
- WLYB 0.22
- SPRY -0.03
- Stochastic Oscillator
- WLYB 84.01
- SPRY 4.66
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.